Abstract
Heterotopic ossification (HO) is a well-known complication of total hip arthroplasty (THA), especially when the direct lateral approach is used. In this study, we examined the effect of the selective COX-2 inhibitor, celecoxib, on the rates of HO after THA. A control group consisting of 108 patients that did not receive celecoxib was compared with a study group consisting of 106 patients that did receive celecoxib. We assessed the presence and grade of HO using the Brooker classification and Harris hip scores were determined pre-and postoperatively to better quantify clinical outcomes. In this retrospective study of prospectively collected data, celecoxib is associated with a significant reduction in the incidence of HO in patients undergoing THA.
Original language | English (US) |
---|---|
Pages (from-to) | 256-262 |
Number of pages | 7 |
Journal | HIP International |
Volume | 24 |
Issue number | 3 |
DOIs | |
State | Published - Jan 1 2014 |
Externally published | Yes |
Keywords
- Celecoxib
- Cyclooxygenase-2
- Heterotopic
- Ossification
- Postoperative complication
- Total hip replacement
ASJC Scopus subject areas
- Surgery
- Orthopedics and Sports Medicine